Taiho Pharmaceutical to Acquire Araris Biotech for $400 Million

Otsuka Holdings Co ( (JP:4578) ) just unveiled an announcement.

Otsuka Holdings Co., Ltd. announced that its subsidiary, Taiho Pharmaceutical, will acquire Swiss biotech company Araris Biotech AG for $400 million, with potential additional milestone payments of up to $740 million. This acquisition will enhance Taiho’s capabilities in developing next-generation ADCs, strengthening its oncology portfolio and positioning it as a leader in innovative cancer therapies.

More about Otsuka Holdings Co

Otsuka Holdings Co., Ltd. operates in the pharmaceutical industry, primarily focusing on oncology and immune-related diseases through its subsidiary, Taiho Pharmaceutical. Taiho is known for developing small-molecule oral therapeutic drugs and is expanding into biologics with a focus on antibody-drug conjugates (ADCs).

YTD Price Performance: -13.10%

Average Trading Volume: 693

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $27.51B

For a thorough assessment of 4578 stock, go to TipRanks’ Stock Analysis page.